CLSD [NASD]
Clearside Biomedical, Inc.
Index- P/E- EPS (ttm)-0.03 Insider Own2.00% Shs Outstand60.06M Perf Week-10.91%
Market Cap88.41M Forward P/E- EPS next Y-0.56 Insider Trans-2.73% Shs Float53.52M Perf Month7.30%
Income0.10M PEG- EPS next Q-0.13 Inst Own27.70% Short Float1.76% Perf Quarter-35.81%
Sales29.90M P/S2.96 EPS this Y101.60% Inst Trans-21.79% Short Ratio3.89 Perf Half Y-46.74%
Book/sh0.53 P/B2.77 EPS next Y0.00% ROA0.20% Target Price9.00 Perf Year-69.57%
Cash/sh0.57 P/C2.57 EPS next 5Y- ROE0.30% 52W Range1.26 - 7.73 Perf YTD-46.55%
Dividend- P/FCF- EPS past 5Y14.90% ROI1.00% 52W High-80.98% Beta2.01
Dividend %- Quick Ratio8.50 Sales past 5Y124.40% Gross Margin- 52W Low16.67% ATR0.11
Employees34 Current Ratio8.50 Sales Q/Q233418.20% Oper. Margin0.30% RSI (14)48.96 Volatility9.64% 7.52%
OptionableYes Debt/Eq0.00 EPS Q/Q1.30% Profit Margin0.30% Rel Volume0.86 Prev Close1.47
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume242.97K Price1.47
Recom2.20 SMA202.40% SMA50-0.57% SMA200-49.13% Volume210,125 Change0.00%
Dec-15-21Resumed Wedbush Outperform $19 → $9
Jul-29-21Initiated H.C. Wainwright Buy $10
May-13-20Initiated ROTH Capital Buy $8
Aug-09-19Downgrade Needham Buy → Hold
Nov-05-18Downgrade Stifel Buy → Hold
Nov-05-18Downgrade JP Morgan Overweight → Underweight
Nov-05-18Downgrade Cowen Outperform → Market Perform
Mar-06-18Reiterated Needham Buy $18 → $22
May-25-17Initiated JMP Securities Mkt Outperform $21
Feb-24-17Initiated JP Morgan Overweight $19
Nov-10-16Reiterated Needham Buy $16 → $24
Oct-24-16Reiterated Stifel Buy $13 → $23
Jun-14-22 07:05AM  
Jun-08-22 07:05AM  
May-11-22 05:25PM  
04:05PM  
May-05-22 07:05AM  
Apr-29-22 07:05AM  
Apr-11-22 07:44AM  
Apr-06-22 07:05AM  
Mar-28-22 06:59AM  
06:59AM  
Mar-15-22 06:38PM  
Mar-10-22 05:25PM  
04:05PM  
Mar-03-22 07:05AM  
Mar-01-22 07:05AM  
Feb-28-22 08:25AM  
Feb-25-22 07:05AM  
Feb-14-22 04:05PM  
Feb-11-22 05:42AM  
Feb-02-22 07:05AM  
Dec-21-21 07:05AM  
Dec-13-21 04:05PM  
05:17AM  
Nov-16-21 07:05AM  
Nov-11-21 07:05AM  
Nov-10-21 05:45PM  
04:05PM  
Nov-03-21 03:00PM  
Oct-29-21 07:12AM  
Oct-28-21 07:05AM  
Oct-25-21 06:45AM  
06:45AM  
Oct-13-21 07:05AM  
Oct-04-21 07:05AM  
Sep-21-21 07:05AM  
Sep-14-21 07:21AM  
Sep-09-21 07:05AM  
Aug-23-21 04:05PM  
Aug-15-21 08:00PM  
Aug-10-21 05:45PM  
04:05PM  
Aug-04-21 07:05AM  
Aug-03-21 03:00PM  
Jul-30-21 02:47AM  
Jul-27-21 04:05PM  
Jun-30-21 09:56AM  
Jun-17-21 07:38PM  
03:38PM  
05:51AM  
Jun-16-21 04:06PM  
08:40AM  
Jun-15-21 10:55AM  
08:54AM  
07:05AM  
02:58AM  
Jun-09-21 07:05AM  
Jun-02-21 06:59AM  
May-17-21 04:05PM  
02:45PM  
May-10-21 03:00PM  
07:05AM  
May-04-21 07:05AM  
May-03-21 07:05AM  
Apr-05-21 07:05AM  
Mar-19-21 01:58AM  
Mar-10-21 05:35PM  
04:05PM  
01:30PM  
07:25AM  
Mar-03-21 12:30PM  
Mar-02-21 07:05AM  
Feb-24-21 07:05AM  
Feb-23-21 07:05AM  
Feb-16-21 07:05AM  
Feb-08-21 07:05AM  
Feb-02-21 05:31AM  
Jan-22-21 10:18AM  
Jan-18-21 12:55AM  
Jan-14-21 08:55AM  
Jan-13-21 12:00PM  
Jan-12-21 07:05AM  
Jan-06-21 07:05AM  
Nov-27-20 04:53PM  
Nov-16-20 07:05AM  
Nov-11-20 07:05AM  
Nov-10-20 04:05PM  
02:45PM  
Oct-30-20 07:05AM  
Oct-27-20 05:24AM  
Sep-23-20 07:05AM  
Sep-11-20 08:30AM  
Sep-09-20 04:05PM  
08:30AM  
Sep-02-20 08:37AM  
Aug-26-20 07:05AM  
Aug-10-20 06:45PM  
04:05PM  
04:02PM  
Aug-04-20 07:05AM  
Aug-03-20 12:31PM  
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Deignan Charles A.Chief Financial OfficerJan 19Sale2.098,83318,461351,366Jan 20 07:07 PM
Ciulla ThomasChief Medical OfficerJan 19Sale2.139,05019,276295,260Jan 20 07:06 PM
LASEZKAY GEORGE MCEOJan 19Sale2.1210,80022,896504,607Jan 20 07:04 PM
LASEZKAY GEORGE MCEOJan 11Sale2.465,10012,546417,907Jan 13 04:40 PM
Humphries William D.DirectorJan 10Option Exercise0.1522,7273,40928,313Jan 11 04:45 PM
Hutson Nancy JDirectorOct 29Option Exercise2.0340,00081,35053,000Nov 02 04:40 PM
Ciulla ThomasChief Medical OfficerSep 21Sale6.402,56016,384255,560Sep 23 05:17 PM
LASEZKAY GEORGE MCEOSep 21Sale6.463,52522,772423,007Sep 23 05:14 PM
Deignan Charles A.Chief Financial OfficerSep 21Sale6.412,80017,948316,449Sep 23 05:12 PM
WHITMORE BRADFORD T10% OwnerSep 01Sale6.89213,2031,469,2462,415,056Sep 01 04:46 PM
WHITMORE BRADFORD T10% OwnerAug 31Sale6.96107,682749,0792,628,259Sep 01 04:46 PM
WHITMORE BRADFORD T10% OwnerAug 30Sale7.0699,400702,1022,735,941Sep 01 04:46 PM
Hutson Nancy JDirectorAug 16Buy5.683,00017,04013,000Aug 17 04:39 PM